SunBio,Inc.
Research SunBio,Inc. (067370.KQ) on Bullrun: market cap KRW 69.09B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker067370.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 69.09B
- Financial periodQ2 2026
- RevenueKRW 2.24B
- Net incomeKRW 631.34M
- Free cash flow-KRW 1.60B
- Gross margin45.4%
Valuation Snapshot
latest market cap is KRW 69.09B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 69.09B | n/a | n/a | n/a |
About SunBio,Inc.
SunBio,Inc., a biotech company, develops, produces, and sells biosimilar and biopharmaceutical products, and medical devices based on its technologies of pegylation worldwide. Its biosimilar products include PEG-filgrastim; and PEG-EPO and uricase which is in preclinical stage. The company offers MucoPEG, a medical device for treatment of dry mouth syndrome; and SynoGEL, a viscosupplement for arthritic Knee. Its preclinical stage biopharmaceuticals candidates target brain stroke and chronic anemia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SunBio,Inc.'s market cap?
SunBio,Inc.'s market capitalization is KRW 69.09B.
What does SunBio,Inc. do?
SunBio,Inc., a biotech company, develops, produces, and sells biosimilar and biopharmaceutical products, and medical devices based on its technologies of pegylation worldwide. Its biosimilar products include PEG-filgrastim; and PEG-EPO and uricase which is in preclinical stage. The company offers MucoPEG, a medical device for treatment of dry mouth syndrome; and SynoGEL, a viscosupplement for arthritic Knee. Its preclinical stage biopharmaceuticals candidates target brain stroke and chronic anemia. It also manufactures and sells PEG derivatives.